Post Menopausal Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Postmenopausal osteoporosis is the most common form of osteoporosis. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture.
The Post Menopausal Osteoporosis pipeline drugs market research report outlays comprehensive information on the Post Menopausal Osteoporosis targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. It also reviews key players involved in Post Menopausal Osteoporosis targeted therapeutics development with respective active and dormant or discontinued projects.
Post Menopausal Osteoporosis Pipeline Drugs Market Segmentation by Targets
Some of the primary targets in the Post Menopausal Osteoporosis pipeline drugs market are Tumor Necrosis Factor Ligand Superfamily Member 11, Parathyroid Hormone Receptor, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor, Sclerostin, Activin Receptor Type 2A, Adrenomedullin, Calcitonin Receptor, Dedicator Of Cytokinesis Protein 5, Estrogen Receptor, and Iron. Tumor Necrosis Factor Ligand Superfamily Member 11 accounted for the largest target in the Post Menopausal Osteoporosis pipeline drugs market.
Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Targets
To know more about the targets in the Post Menopausal Osteoporosis pipeline drugs market, download a free report sample
Post Menopausal Osteoporosis Pipeline Drugs Market Segmentation by Mechanisms of Action
The primary mechanisms of action in the Post Menopausal Osteoporosis pipeline drugs market are Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor, Parathyroid Hormone Receptor Agonist, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor Agonist, Sclerostin Inhibitor, Calcitonin Receptor Agonist, Dedicator Of Cytokinesis Protein 5 Inhibitor, Estrogen Receptor Agonist, Iron Chelator, Parathyroid Hormone Activator, Tumor Necrosis Factor Receptor Superfamily Member 11A Inhibitor, and Vitamin D Receptor Agonist. Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor has the maximum number of products in the Post Menopausal Osteoporosis pipeline drugs market.
Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Mechanisms of Action
To know more about the MoA in the Post Menopausal Osteoporosis pipeline drugs market, download a free report sample
Post Menopausal Osteoporosis Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Post Menopausal Osteoporosis pipeline drugs market are subcutaneous, oral, parenteral, transdermal, and intravenous. Subcutaneous has the majority number of products in the Post Menopausal Osteoporosis pipeline drugs market.
Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Routes of Administration
To know more about the RoA in the Post Menopausal Osteoporosis pipeline drugs market, download a free report sample
Post Menopausal Osteoporosis Pipeline Drugs Market Segmentation by Molecule Type
The key molecule types in the Post Menopausal Osteoporosis pipeline drugs market are Monoclonal Antibody, Recombinant Peptide, Recombinant Protein, Small Molecule, Synthetic Peptide, Biologic, and Gene Therapy.
Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Molecule Type
To know more about the molecule type in the Post Menopausal Osteoporosis pipeline drugs market, download a free report sample
Competitive Landscape
Some of the leading companies in the Post Menopausal Osteoporosis pipeline drugs market are Biocon Ltd, Eden Biologics Inc, Enteris BioPharma Inc, Ipsen SA, Luye Pharma Group Ltd, Shanghai Henlius Biotech Inc, Uni-Bio Science Group Ltd, Ablynx NV, Addpharma Inc, and Airsea (Taizhou) Pharmaceutical Ltd. Biocon Ltd accounted for the largest Post Menopausal Osteoporosis pipeline drugs market share in 2022.
Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Leading Companies
To know more about the leading companies in the Post Menopausal Osteoporosis pipeline drugs market, download a free report sample
Post Menopausal Osteoporosis Pipeline Drugs Market Report Overview
Key Targets | Tumor Necrosis Factor Ligand Superfamily Member 11, Parathyroid Hormone Receptor, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor, Sclerostin, Activin Receptor Type 2A, Adrenomedullin, Calcitonin Receptor, Dedicator Of Cytokinesis Protein 5, Estrogen Receptor, and Iron |
Key Mechanisms of Action | Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor, Parathyroid Hormone Receptor Agonist, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor Agonist, Sclerostin Inhibitor, Calcitonin Receptor Agonist, Dedicator Of Cytokinesis Protein 5 Inhibitor, Estrogen Receptor Agonist, Iron Chelator, Parathyroid Hormone Activator, Tumor Necrosis Factor Receptor Superfamily Member 11A Inhibitor, and Vitamin D Receptor Agonist |
Key Routes of Administration | Subcutaneous, Oral, Parenteral, Transdermal, and Intravenous |
Key Molecule Types | Monoclonal Antibody, Recombinant Peptide, Recombinant Protein, Small Molecule, Synthetic Peptide, Biologic, and Gene Therapy |
Key Companies | Biocon Ltd, Eden Biologics Inc, Enteris BioPharma Inc, Ipsen SA, Luye Pharma Group Ltd, Shanghai Henlius Biotech Inc, Uni-Bio Science Group Ltd, Ablynx NV, Addpharma Inc, and Airsea (Taizhou) Pharmaceutical Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Addpharma Inc
Airsea (Taizhou) Pharmaceutical Ltd
AlphaMab Co Ltd
Alvotech SA
Amgen Inc
Aryogen Pharmed Co
Beijing Kangleweishi Biotechnology Co Ltd
Beijing Northland Biotech Co Ltd
Biocon Ltd
Celltrion Inc
Clayton Biotechnologies Inc
Clonz Biotech Pvt Ltd
CSPC Pharmaceutical Group Ltd
Eden Biologics Inc
Eli Lilly and Co
Entera Bio Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Epygen Biotech Pvt Ltd
Fresenius Kabi SwissBioSim GmbH
Gedeon Richter Plc
Genor BioPharma Co Ltd
Hualan Biological Engineering Inc
Intas Pharmaceuticals Ltd
Ipsen SA
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu T-mab BioPharma Co Ltd
Lupin Ltd
Luye Pharma Group Ltd
Mabxience Holding SL
Nano Intelligent Biomedical Engineering Corp
Nanomedic Inc
NeuClone Pty Ltd
Paras Biopharmaceuticals Finland Oy
Qilu Pharmaceutical Co Ltd
Reliance Life Sciences Pvt Ltd
Samsung Bioepis Co Ltd
Sandoz International GmbH
Shandong New Time Pharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Mab Venture Biopharm Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Teva Pharmaceutical Industries Ltd
Uni-Bio Science Group Ltd
Wuxi Hebang Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets in the Post Menopausal Osteoporosis pipeline drugs market?
Some of the targets in the Post Menopausal Osteoporosis pipeline drugs market are Tumor Necrosis Factor Ligand Superfamily Member 11, Parathyroid Hormone Receptor, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor, Sclerostin, Activin Receptor Type 2A, Adrenomedullin, Calcitonin Receptor, Dedicator Of Cytokinesis Protein 5, Estrogen Receptor, and Iron.
-
What are the mechanisms of action in the Post Menopausal Osteoporosis pipeline drugs market?
The primary mechanism of action in the Post Menopausal Osteoporosis pipeline drugs market are Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor, Parathyroid Hormone Receptor Agonist, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor Agonist, Sclerostin Inhibitor, Calcitonin Receptor Agonist, Dedicator Of Cytokinesis Protein 5 Inhibitor, Estrogen Receptor Agonist, Iron Chelator, Parathyroid Hormone Activator, Tumor Necrosis Factor Receptor Superfamily Member 11A Inhibitor, and Vitamin D Receptor Agonist.
-
What are the routes of administration in the Post Menopausal Osteoporosis pipeline drugs market?
The routes of administration in the Post Menopausal Osteoporosis pipeline drugs market are subcutaneous, oral, parenteral, transdermal, and intravenous.
-
What are the molecule types in the Post Menopausal Osteoporosis pipeline drugs market?
The molecule types in the Post Menopausal Osteoporosis pipeline drugs market are Monoclonal Antibody, Recombinant Peptide, Recombinant Protein, Small Molecule, Synthetic Peptide, Biologic, and Gene Therapy.
-
Which are the leading companies in the Post Menopausal Osteoporosis pipeline drugs market?
Some of the leading companies in the Post Menopausal Osteoporosis pipeline drugs market are Biocon Ltd, Eden Biologics Inc, Enteris BioPharma Inc, Ipsen SA, Luye Pharma Group Ltd, Shanghai Henlius Biotech Inc, Uni-Bio Science Group Ltd, Ablynx NV, Addpharma Inc, and Airsea (Taizhou) Pharmaceutical Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.